Table 5 Multivariate analyses

In vivo T cell depletion

0.0001

0.46 (0.31–0.68)

0.094

0.59 (0.32–1.09)

0.149

0.72 (0.46–1.12)

0.027

0.67 (0.46–0.95)

0.027

0.65 (0.44–0.95)

4 × 10⁻⁵

0.51 (0.37–0.70)

Age at SCT >50 years

0.447

1.13 (0.82–1.57)

0.012

1.83 (1.14–2.94)

0.083

1.39 (0.96–2.00)

0.004

1.53 (1.15–2.05)

0.026

1.42 (1.04–1.93)

0.037

1.32 (1.02–1.71)

Interval diag. to SCT^a

0.465

1.05 (0.91–1.22)

0.209

1.00 (1.00–1.00)

0.974

1.00 (1.00–1.00)

0.461

1.00 (1.00–1.00)

0.410

1.00 (1.00–1.00)

0.717

1.00 (1.00–1.00)

Year of SCT

0.929

1.00 (1.00–1.00)

0.894

0.99 (0.87–1.30)

0.862

1.01 (0.91–1.12)

0.960

1.00 (0.92–1.09)

0.558

0.98 (0.90–1.06)

0.522

0.98 (0.91–1.05)

Secondary AML

0.033

1.68 (1.04–2.72)

0.232

1.55 (0.76–3.19)

0.434

1.26 (0.71–2.26)

0.192

1.35 (0.86–2.12)

0.163

1.40 (0.87–2.25)

0.058

1.47 (0.99–2.18)

Female D to male R

0.001

1.75 (1.27–2.43)

0.669

1.12 (0.66–1.90)

0.319

1.22 (0.82–1.82)

0.306

1.18 (0.86–1.62)

0.253

1.21 (0.87–1.69)

0.0004

1.62 (1.24–2.11)

R CMV seropositivity

0.231

1.32 (0.84–2.09)

0.851

0.93 (0.46–1.90)

0.733

0.91 (0.55–1.53)

0.651

0.91 (0.60–1.38)

0.456

0.85 (0.55–1.31)

0.639

0.92 (0.64–1.32)

D CMV seropositivity

0.417

1.17 (0.81–1.68)

0.241

1.49 (0.77–2.89)

0.812

1.06 (0.67–1.68)

0.358

1. 20 (0.82–1.75)

0.359

1.21 (0.81–1.80)

0.832

1.04 (0.75–1.42)

Center (frailty variable)

0.0007

0.047

0.211

0.917

0.913

0.154